Abstract: Diphosphonate-derivatized macromolecules, such as proteins, suitable for use as technetium-99m-based scanning agents and as anticalcification agents are disclosed. The scanning agents are prepared by combining Tc-99m in a +3, +4 and/or +5 oxidation state with the diphosphonate-derivatized macromolecules. Also disclosed are pharmaceutical compositions containing these diphosphonate-derivatized macromolecules and methods for scintigraphic imaging using these diphosphonate-derivatized macromolecules labeled with Tc-99m.

Abstract: A method for treating or preventing osteoporosis is disclosed. Bone cells are synchronized during a bone cell activating period; bone resorption, which normally follows activation, is inhibited using a polyphosphonate; bone formation is allowed to occur in the rest period during which nutrient supplements may be administered to the patient. The method shortens the natural cycle time of bone formation/resorption, resulting in a faster bone build-up.

Abstract: The invention involves a method for achieving systemic administration of azumolene by delivering the drug to the intestines without exposing the drug in the stomach, and pharmaceutical compositions for achieving such administration of azumolene.

Abstract: A kit for use in the treatment of osteoporosis is disclosed. The kit comprises a bone cell activating compound, a bone resorption inhibiting polyphosphonate, and a nutrient supplement or placebo, for sequential administration.

Abstract: An analgesic composition comprising capsaicin or a capsaicin analogue and an analgesic selected from the class of non-steroidal anti-inflammatory, antipyretic and analgesic drugs is disclosed. This combination has been found to exhibit unexpectedly enhanced analgesic activity in humans and lower animals without a corresponding increase in undesirable side effects.

Abstract: A method for treating or preventing osteoporosis is disclosed. Bone cells are synchronized during a bone cell activating period; bone resorption, which normally follows activation, is inhibited using a polyphosphonate; bone formation is allowed to occur in the rest period during which nutrient supplements may be administered to the patient.

Abstract: This invention relates to pharmaceutical compositions comprising anaerobe-selective antibacterial agents which are substituted or unsubstituted 1,12-dodecanedioic peroxy acids, or their pharmaceutically-acceptable salts or esters. The pharmaceutical compositions of the present invention are especially suitable for oral administration in the form of mouth rinses and toothpastes. These anaerobe-selective antibacterial compositions are useful for treating or preventing anaerobic bacterial infections, especially diseases of the oral cavity, in humans or lower animals.The present invention further relates to a method for treating or preventing anaerobic bacterial infections such as acne, and especially diseases of the oral cavity such as gingivitis and periodontal disease, in humans or lower animals.

Abstract: The present invention involves compounds of the class of acylphosphorotriamides and methods for altering the blood plasma lipid content of mammals which comprises systemically administering to mammals an effective but nontoxic amount of a composition comprising such compounds.

Abstract: The invention involves a sustained release pharmaceutical capsule for oral administration comprising, in a capsule shell, a particulate mixture comprising an active drug ingredient which is a weak acid, neutral, or a weak base, polyvinylpyrrolidone, and carboxyvinylpolymer.

Abstract: The invention involves a combination sustained release/rapid release pharmaceutical capsule for oral administration of nitrofurantoin comprising, in a capsule shell, a first layer of a first particulate mixture comprising nitrofurantoin, polyvinylpyrrolidone and carboxyvinylpolymer; and a second layer of a second particulate mixture comprising macrocrystalline nitrofurantoin.

Abstract: A method for treating or preventing osteoporosis utilizing a cyclic regimen comprising alternating for two or more cycles the administration of a bone resorption inhibiting polyphosphonate and a no treatment (rest) period. Further disclosed is a kit for use in implementing this method of treatment.

Abstract: The present invention involves compounds of the class of imidazo[4,5-f]quinolines and methods for enhancing the immune response system of mammals which comprises systemically administering to mammals having a depressed immune function an effective but nontoxic amount of a composition comprising such a compound.

Abstract: The present invention provides for a process for transforming a substantially continuous web of substantially planar, deformable material having an indefinite length, a first surface, and a second surface into a formed material. The material has a transformation temperature range. The process comprises the following steps:(a) The web of material is provided on a forming structure with the first surface of the web of material proximate a forming surface of the forming structure. The forming surface moves in a direction of the length of the web of material and carries the web of material in that direction.(b) A liquid stream is applied to the second surface of the web of material. The liquid stream has sufficient force and mass flux to cause the web of material to be deformed toward the forming surface, such that the material acquires a substantial three-dimensional conformation.

Abstract: Novel cyclic geminal-diphosphonic acid compounds, and pharmaceutical compositions containing these compounds, which are useful for treating diseases characterized by abnormal calcium and phosphate metabolism; and a method of treating diseases characterized by abnormal calcium and phosphate metabolism utilizing these noval cyclic diphosphonic acid compounds.

Abstract: A furazolidone dosage unit form comprises the drug furazolidone, a sustained release matrix, and an enteric coating.

Abstract: The present invention involves compounds of the class of acylphosphorotriamides and methods for altering the blood plasma lipid content of mammals which comprises systemically administering to mammals an effective but nontoxic amount of a composition comprising such compounds.

Abstract: Certain 5-phenyl-2-furoic acid hydrazides of the formula: ##STR1## wherein X represents 4-chloro, 4-fluoro, 3-trifluoromethyl or hydrogen, R.sub.1 represents hydrogen or methyl, R.sub.2 represents acetyl, isopropyl or methyl, and R.sub.1 and R.sub.2 taken together represent isopropylidene or 4-pyridinylmethylene are useful as anti-inflammatory agents.

Abstract: The invention involves compositions useful for treating certain malignant tumors with the compound ethyl 4-hydroxy-2-[(5-morpholinomethyl-2-oxo)-3-oxazolidinyliminomethyl]furo[2,3 -b]pyridine-5-carboxylate (Compound I) or its pharmaceutically acceptable salts or hydrates.

Abstract: The present invention provides a layered absorbent structure, the structure having an upper surface and a lower surface. The structure comprises:(a) n webs of fibrous material, n being an integer of two or more. The webs are layered such that there is an uppermost web, a lowermost web, n-2 intermediate webs, and n-1 interfaces of two opposed adjacent contacting surfaces of adjacent webs. Each of the interfaces has a surface area.(b) Absorbent particles forming a discontinuous layer at one or more of the interfaces.The opposed adjacent contacting surfaces at each interface where particles are present are substantially entirely frangibly bonded by fiber entanglement between the contacting surfaces. The particles are immobilized at said interface(s) substantially entirely by fiber entrapment.

Abstract: The present invention provides a layered absorbent structure, the structure having an upper surface and a lower surface. The structure comprises:(a) n webs of fibrous material, n being an integer of two or more. The webs are layered such that there is an uppermost web, a lowermost web, n-2 intermediate webs, and n-1 interfaces of two opposed adjacent contacting surfaces of adjacent webs. Each of the interfaces has a surface area.(b) Absorbent particles forming a discontinuous layer at one or more of the interfaces.The opposed adjacent contacting surfaces at each interface where particles are present are substantially entirely frangibly bonded by fiber entanglement between the contacting surfaces. The particles are immobilized at said interface(s) substantially entirely by fiber entrapment.